Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

09 December 2009

Safety of mycophenolate mofetil monotherapy in patients after liver transplantation.

Carsten Kamphues, Roberta Bova, Christoph Röcken, Ruth Neuhaus, Johann Pratschke, Peter Neuhaus, Ulf P. Neumann

Ann Transplant 2009; 14(4): 40-46 :: ID: 880553

Abstract

Background:
Due to the nephrotoxicity of calcineurin inhibitors (CNIs) mycophenolate mofetil (MMF) has become a promising immunosuppressive alternative in recent years. In several studies an improvement of renal function could be reached by introduction of MMF and withdrawal of CNIs but there is few known about the long-term effects of MMF on liver-, kidney- and bone marrow function.
Material and Methods:
We therefore retrospectively reviewed 123 adult liver transplant patients who were successfully converted to MMF monotherapy without any acute rejection within the first three months of MMF monotherapy.
Results:
Serum levels of liver enzymes as well as white blood cells did not show any significant difference between the time of conversion and after 1 year but a significant reduction in serum creatinine could be evaluated (1.47 mg/dl vs. 1.54 mg/dl). In 59 patients liver biopsies were performed before and after introduction of MMF monotherapy. None displayed signs of chronic rejection during MMF monotherapy but there was a slight increase of the fat content of the liver (16.1% vs. 9.8%).
Conclusions:
In conclusion after successful conversion to MMF monotherapy this regime is safe and effective and the long-term effects of MMF monotherapy on the liver tissue are minor. Furthermore renal function can be improved without considerable effects on the bone marrow.

Keywords: Mycophenolate Mofetil

Add Comment 0 Comments

In Press

Original article  

Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...

Ann Transplant In Press; DOI: 10.12659/AOT.951568  

Original article  

Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver Transplantation

Ann Transplant In Press; DOI: 10.12659/AOT.950589  

Database Analysis  

Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...

Ann Transplant In Press; DOI: 10.12659/AOT.950289  

Original article  

Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...

Ann Transplant In Press; DOI: 10.12659/AOT.950997  

Most Viewed Current Articles

24 Aug 2021 : Review article   18,372

Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives

DOI :10.12659/AOT.931664

Ann Transplant 2021; 26:e931664

05 Apr 2022 : Original article   14,731

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

22 Nov 2022 : Original article   14,244

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

29 Dec 2021 : Original article   13,752

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358